Back to Search
Start Over
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
- Source :
- The Lancet Regional Health-Europe, The Lancet Regional Health-Europe, Elsevier, 2021, 8, pp.100171. ⟨10.1016/j.lanepe.2021.100171⟩, The Lancet Regional Health-Europe, 2021, 8, pp.100171. ⟨10.1016/j.lanepe.2021.100171⟩, The Lancet Regional Health. Europe, Vol 8, Iss, Pp 100171-(2021), The Lancet Regional Health. Europe
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- Background: We aimed to assess the effectiveness of two doses of mRNA COVID-19 vaccines against COVID-19 with the original virus and other lineages circulating in France. Methods: In this nationwide case-control study, cases were SARS-CoV-2 infected adults with onset of symptoms between 14 February and 3 May 2021. Controls were non-infected adults from a national representative panel matched to cases by age, sex, region, population density and calendar week. Participants completed an online questionnaire on recent activity-related exposures and vaccination history. Information about the infecting virus was based on a screening RT-PCR for either B.1.1.7 or B.1.351/P.1 variants. Findings: Included in our analysis were 7 288 adults infected with the original SARS-CoV-2 virus, 31 313 with the B.1.1.7 lineage, 2 550 with B.1.351/P1 lineages, and 3 644 controls. In multivariable analysis, the vaccine effectiveness (95% confidence interval) seven days after the second dose of mRNA vaccine was estimated at 88% (81-92), 86% (81-90) and 77% (63-86) against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively. Recent (2 to 6 months) history of virologically confirmed SARS-CoV-2 infection was found to be 83% (76-88), 88% (85-91) and 83% (71-90) protective against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively; and more distant (> 6 months) infections were 76% (54-87), 84% (75-90), and 74% (41-89) protective against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively. Interpretation: In real-life settings, two doses of mRNA vaccines proved to be effective against COVID-19 with the original virus, B.1.1.7 lineage and B.1.351/P.1 lineages. Funding: Institut Pasteur, Research & Action Emerging Infectious Diseases (REACTing), Fondation de France (Alliance “Tous unis contre le virus”).
- Subjects :
- medicine.medical_specialty
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Lineage (evolution)
case-control study
Biology
Virus
03 medical and health sciences
0302 clinical medicine
Epidemiology
Internal Medicine
medicine
030212 general & internal medicine
030304 developmental biology
Vaccine effectiveness
0303 health sciences
Messenger RNA
SARS-CoV-2 variants
Health Policy
Case-control study
COVID-19
Virology
Confidence interval
3. Good health
Vaccination
Oncology
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
epidemiology
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Public aspects of medicine
RA1-1270
Research Paper
Subjects
Details
- Language :
- English
- ISSN :
- 26667762
- Database :
- OpenAIRE
- Journal :
- The Lancet Regional Health-Europe, The Lancet Regional Health-Europe, Elsevier, 2021, 8, pp.100171. ⟨10.1016/j.lanepe.2021.100171⟩, The Lancet Regional Health-Europe, 2021, 8, pp.100171. ⟨10.1016/j.lanepe.2021.100171⟩, The Lancet Regional Health. Europe, Vol 8, Iss, Pp 100171-(2021), The Lancet Regional Health. Europe
- Accession number :
- edsair.doi.dedup.....3751f40b74a7d0cee2d1fd24ace562c6